Portfolio Lab

Halozyme Therapeutics, Inc.

  • Stock
  • Ticker HALO
  • ISIN US40637H1095
  • Nasdaq

Health care · Biotechnology · USA

$91.35 −1.82%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Halozyme Therapeutics, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

HALOGlobal equities (VT)

$10,000 grew to $72,271. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −49.1% in 05/2023, measured from the peak in 12/2022. It took 21 months to get back to the old peak.

1-year return
+32.4%
5-year return p.a.
+20.8%
10-year return p.a.
+21.9%
Volatility p.a.
41.9%
Largest decline
−49.1%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue298265326354452377481493
Gross profit256216279299373297402410
Operating income176142202218-93185288295
EBITDA178144205221-90189292300
Net income137118165175-142150230247
Earnings per share1.060.931.331.43-1.121.221.902.01
Balance sheet
Total assets2,0632,1972,0542,2212,5252,6732,5773,473
Liabilities1,7001,7141,7211,7172,4772,4532,4343,529
Equity36448233350449220144-55
Cash116176624201343101631,030
Long-term debt1,5061,5071,5098002,1431,9361,9382,945
Cash flow
Operating cash flow178154100179219180241258
Capital expenditure-3.1-1.0-1.6-3.0-1.4-3.7-4.2-3.1
Free cash flow17515398176218176237255

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +140.9%, weakest 2023 at −35.0%. 6 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026$2.01
6 Aug 2026$1.90
11 May 2026$1.22
17 Feb 2026−$1.12
3 Nov 2025$1.43
5 Aug 2025$1.33
6 May 2025$0.93
18 Feb 2025$1.06
31 Oct 2024$1.05
6 Aug 2024$0.72
7 May 2024$0.60
20 Feb 2024$0.65

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€9.4bn
Market cap in trading currency
$10.4bn
Enterprise value
$12.6bn
P/E
22.8
P/S
5.78
P/B
–
EV/Sales
7.01
EV/EBITDA
18.3
Earnings yield
4.4%
FCF yield
8.5%

Results (last four quarters)

Revenue
$1.80bn
Gross profit
$1.48bn
EBITDA
$691m
Net income
$485m
Earnings per share
$4.01
Revenue per share
$15.81
Revenue growth
+39.2%
Earnings growth
+41.0%

Profitability

Gross margin
82.3%
Operating margin
37.4%
Net margin
26.9%
Return on equity
–
Return on assets
14.0%

Balance sheet and cash flow

Cash
$1.03bn
Cash per share
$9.03
Financial debt
$3.25bn
Debt/equity %
–
Current ratio
3.88
Book value per share
−$0.48
Operating cash flow
$898m
Free cash flow
$886m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
114m
Volume
1.46m
Avg. volume 3 months
2.25m
Relative volume
0.6

Price and technicals

Price
$91.35
1 day
−1.8%
52-week high
$131.18
52-week low
$61.63
Distance to 52-week high
−30.4%
Distance to 52-week low
+48.2%
Distance to 50-day line
−19.3%
Distance to 200-day line
+6.4%
RSI (14)
20
Volatility 1M
63.7%

Performance

1 week
−8.9%
1 month
−26.7%
3 months
−15.9%
6 months
+33.7%
YTD
+35.7%
1 year
+30.0%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has HALO performed since 11/2016?

$10,000 grew to $72,271 by 20 Nov 2026, which is +21.9% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is HALO?

Volatility was 41.9% per year, measured on monthly returns. The largest decline from a peak was −49.1%, with the low in 05/2023.

How does HALO compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, HALO returned +21.9% at 41.9%. The correlation of monthly returns was 0.45; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Halozyme Therapeutics, Inc. (HALO): Return and risk